TendenzaMercati

Segnali Operativi su Azioni Italia, Azioni USA, Futures e Forex

Pfizer to acquire Medivation for $14 billion in cash

Pfizer will acquire Medivation for $81.50 a share in cash for a total enterprise value of approximately $14 billion.

pfizer medivationPfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.

The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.

The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer,” said Ian Read, chairman and chief executive officer, Pfizer.

Pfizer expects to finance the transaction with existing cash.

STRATEGIE OPERATIVE

Segnali operativi sia al rialzo (Long) che al ribasso (Short) su azioni italiane ed americane, futures e forex

PERFORMANCE STRATEGIE

Analisi Tecnica

Intesa Sanpaolo: prende corpo ipotesi rialzista

Intesa Sanpaolo: prende corpo ipotesi rialzista

Il superamento di area 2.2080 lascia spazio all’ipotesi di continuazione dell’ascesa per Intesa Sanpaolo in direzione…

Edit Template

Copyright © 2006-2022. Tutti i diritti riservati. Powered by Royal Web Design.